RayKnowChina Research Map
Shortlist0

RecruitingMoyamoya diseasePhase 1

Registered title, quoted from ClinicalTrials.gov

Treatment of Moyamoya Disease With iPSC-derived Exosomes

An open trial on moyamoya disease, registered on ClinicalTrials.gov. Led by Tongji Hospital; 0 other hospitals on this site are listed as study sites.

Status, phase and start date as registered on ClinicalTrials.gov on 8 Nov 2026; the registry may have changed since. Whether someone can take part is decided by the study team. Not medical advice.

The study team’s contact details are on the registry record. This site does not pass on enquiries.

Hospitals in mainland China listed for this trial 1

Hospitals on this site that the registry record names as lead sponsor or study site, where the site is open. Lead sponsor first, then study sites A–Z.

  1. Lead (inferred)Tongji Hospital华中科技大学同济医学院附属同济医院WuhanHospital page

The record may name more sites, including outside mainland China, and sites can open or close during a trial. Full list of sites on ClinicalTrials.gov

Source: ClinicalTrials.gov record NCT07065409, read on 8 Nov 2026; hospital names matched to this site’s hospital list. How names are matched

Checklist for this trial 4

Only the points this trial’s record answers definitely: the registered age and sex, and criteria lines that state a number, score, stage or named test, quoted word for word. Tick a point once it has been compared with the medical records.

Show the checklist (4 points)Hide the checklist
  1. 18 years to 75 years; sex: all

    Registered eligibility fields

  2. Patients have been followed up for ≥ 3 months since the surgery.

    Inclusion criterion 4

    Vascular DSA performed 3 months after the surgery indicates poor blood flow reconstruction.

    Inclusion criterion 5

    CTP or ASL performed 3 months after the surgery shows ischemia.

    Inclusion criterion 6

    Patients still have clinical manifestations of cerebral ischemia or cerebral infarction due to MMD 3 months after the surgery.

    Inclusion criterion 7

  3. Relevant bone marrow, liver, kidney, and heart function indicators meet the following standards (based on the normal values of the clinical trial center): absolute neutrophil count (ANC) ≥ 1.5×109/L, platelets ≥ 100×109/L, total serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), ALT, AST, or ALP ≤ 3 times ULN; serum creatinine ≤ 1.5 times ULN, international normalized ratio (INR) ≤ 1.5 times ULN, APTT ≤ 1.5 times ULN.

    Inclusion criterion 2

  4. Pregnant women, lactating women, and patients with plans to conceive during the trial period;

    Exclusion criterion 8

Ticks stay on this page; they are not saved or sent. Meeting every point is not enough: the study team decides after its own screening. Lines that need the team’s judgement, such as “sufficient organ function”, are not in this list; they are in the full criteria below. Not stated definitely in this record: diagnosis and how it was confirmed; stage or severity, as the trial defines it; day-to-day activity level; scans and measurable lesions; other conditions the trial excludes.

Questions to ask the study team

Picked from the record by fixed keyword rules (not by AI, not checked by hand) and quoted from ClinicalTrials.gov, NCT07065409, read on 10 Nov 2026.

Registered criteria

Quoted as registered on ClinicalTrials.gov, in English, read on 10 Nov 2026. This site has not checked, shortened or translated them. Meeting the written criteria is not enough: the study team decides after its own screening.

Inclusion criteria:

  • Diagnosed adult patients with MMD aged 18-75 years (inclusive), with bilateral terminal occlusion of the internal carotid arteries (ICA) and stenosis or occlusion of the anterior cerebral artery (ACA) and middle cerebral artery (MCA) at the origin, accompanied by the formation of abnormal vascular networks at the base of the skull, as indicated by head DSA or MRA. Unilateral or bilateral lesions are acceptable. Suzuki score ≥ 3.
  • Relevant bone marrow, liver, kidney, and heart function indicators meet the following standards (based on the normal values of the clinical trial center): absolute neutrophil count (ANC) ≥ 1.5×109/L, platelets ≥ 100×109/L, total serum bilirubin ≤ 1.5 times the upper limit of normal (ULN), ALT, AST, or ALP ≤ 3 times ULN; serum creatinine ≤ 1.5 times ULN, international normalized ratio (INR) ≤ 1.5 times ULN, APTT ≤ 1.5 times ULN.
  • Patients have undergone temporal muscle patch surgery and have not achieved satisfactory improvement in symptoms.
  • Patients have been followed up for ≥ 3 months since the surgery.
  • Vascular DSA performed 3 months after the surgery indicates poor blood flow reconstruction.
  • CTP or ASL performed 3 months after the surgery shows ischemia.
  • Patients still have clinical manifestations of cerebral ischemia or cerebral infarction due to MMD 3 months after the surgery.
  • Patients or their legal representatives have given informed consent and signed the informed consent form.

Exclusion criteria:

  • Patients with severe liver or kidney dysfunction or other complications;
  • Patients with a history of mental disorders or mental diseases;
  • Patients with coagulation disorders;
  • Patients with extensive cerebral infarction or in a coma;
  • Patients who only undergo direct bypass surgery;
  • Patients who have not signed the surgical consent form;
  • Patients with allergic constitutions or a clear history of allergies;
  • Pregnant women, lactating women, and patients with plans to conceive during the trial period;
  • Patients who have participated in other clinical trials in the past three months;
  • Patients deemed unsuitable for the trial by the researcher.

Quoted from ClinicalTrials.gov, NCT07065409, participation criteria. Read on 10 Nov 2026.

Where this information comes from

The registry record

ClinicalTrials.gov (US National Library of Medicine), record NCT07065409, read on 8 Nov 2026. A trial has a page here while its overall status is recruiting, not yet recruiting or enrolling by invitation and at least one listed hospital’s site is open. Trials registered only in China’s own registry (ChiCTR) are not included.

Diseases and hospitals

The trial is listed under a disease when this site’s ClinicalTrials.gov search for that disease in China returns it. Sponsor and site names in the record are matched to this site’s hospital list (ROR identifiers, checked aliases). Definitions

What is left out

Names of investigators and contact persons in the record, and anything not in the record. The title and criteria are quoted from the record.

Suggest a correctionClinicalTrials.gov NCT07065409